Goldman Sachs analyst Davin Thillainathan initiated coverage of CSL (CSLLY) with a Buy rating and A$325.40 price target The firm believes the company’s investments in its immunoglobulin franchise and new product launches in the Behring portfolio are set to increase return on invested capital.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CSLLY: